RTW Investments, L.P., 10% Owner at Kailera Therapeutics, Inc. (KLRA), bought 500,000 shares at $16.00 ($8.0M) on 2026-04-20, disclosed to the SEC on 2026-04-22.
RTW Investments purchased $8M of KLRA shares at $16, marking the largest insider purchase in the company's history. This significant bet by a major holder coincides with the stock's recent rally from its IPO price of $16 to $24.30, suggesting confidence in the obesity drug pipeline.
KLRA is currently trading 13.91% below its 52-week high of $28.23 and 2.75% above its 52-week low of $23.65.
William Blair initiated coverage on May 13, 2026, highlighting the obesity drug pipeline; the company completed its IPO and governance overhaul on May 1, 2026; and RTW Investments executed the largest-ever purchase of $8M on April 20, 2026.
The stock is down 13.91% from its 52-week high of $28.23, and the industry buy percentage over the last 90 days is negative at -0.0101.
Negative factors outweigh the positive ones.
| Filing → |
| DMTK | SELL | 2022-11-08 | $177K | — | Filing → |
| RCKT | BUY | 2022-10-11 | $20.0M | — | Filing → |
| LABP | SELL | 2022-09-27 | $414K | — | Filing → |